Context Therapeutics (NASDAQ:CNTX) Stock Rating Upgraded by Wall Street Zen

Context Therapeutics (NASDAQ:CNTX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other equities analysts also recently weighed in on CNTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research report on Wednesday, January 21st. HC Wainwright increased their price objective on Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Jones Trading initiated coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Finally, D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Thursday, November 6th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Context Therapeutics Trading Up 5.7%

Shares of CNTX opened at $2.61 on Friday. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.85. The stock has a market cap of $239.81 million, a P/E ratio of -10.88 and a beta of 1.91. The company has a 50-day moving average of $1.40 and a two-hundred day moving average of $1.13.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Trading of Context Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Clear Harbor Asset Management LLC increased its stake in shares of Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the third quarter worth approximately $100,000. Finally, Vanguard Group Inc. grew its holdings in Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares during the period. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.